At Windhover's Pharmaceutical Strategic Alliances meeting in September in New York, executives from large pharmaceutical companies elaborated on the benefits of size—in terms of absorbing R&D or market turbulence, generating cost savings, and enabling geographic reach.
But fittingly for a conference where the theme asked if companies can be large and small at once, much of...